Skip to main content
. 2016 Dec 19;18(1):150–168. doi: 10.15252/embr.201642360

Figure 8. A combinational treatment of the proteasome inhibitor MG132 and UPR blocker STK047915 synergistically inhibits the tumor formation of GSCs.

Figure 8

  • A, B
    XO8 GSCs were subcutaneously (s.c.) injected in the flank of mice (n = 5). When the tumor volume reached approximately 180 mm3, GSC‐bearing mice were administered intraperitoneally (i.p.) with 1 mg/kg MG132 and 10 mg/kg STK alone or in combination on every day for 2 weeks. Tumors were dissected from the subcutaneous regions of nude mice. Inset picture shows the tumor in respective group. Therapeutic effects were monitored using bioluminescence imaging.
  • C
    On each day of treatment as outlined in (A, B), tumor volume was calculated. Error bars represent the mean ± SD from five calculations (***P < 0.0037). For statistical analysis, Student's t‐test (two‐sided, paired) was used.
  • D
    On each day of treatment as outlined in (A, B), total tumor weight was measured. Error bars represent the mean ± SD from five measurements.
  • E
    On each day of treatment as outlined in (A, B), tumor size was calculated. Error bars represent the mean ± SD from five calculations. For statistical analysis, Student's t‐test (two‐sided, paired) was used. P‐values: *, 0.0388; **, 0.0153.
  • F
    XO10 GSC were orthotopically injected into the brains of BALB/c nude mice. STK047915, MG132, or both were injected intraperitoneally to GSC‐bearing mice at day 14 after XO10 (5 × 105 cells) inoculation. The PBS was used as a control. Representative photographs of H&E staining from each group show tumor growth. Magnification, ×1.